Regeneron Pharmaceuticals
Regeneron Pharmaceuticals/ US75886F1075 /
REGN
8/30/2024 7:54:53 PM
|
Chg.
-0.41
|
Volume |
Bid- |
Ask- |
Market Capitalization |
Dividend Y. |
P/E Ratio |
1,178.68USD
|
-0.03%
|
7,704 Turnover: 9.1 mill. |
-Bid Size: - |
-Ask Size: - |
129.7 bill.USD |
- |
31.76 |
Fundamentals
|
FY 2023 |
Growth (1Y) |
Per Share |
|
Earnings per Share: |
37.05 USD |
-8.54% |
EPS Diluted: |
34.77 USD |
-9.03% |
Revenues per Share: |
121.52 USD |
7.32% |
Book Value per Share: |
240.62 USD |
14.14% |
Cash Flow per Share: |
42.56 USD |
-8.76% |
Dividend per Share: |
- USD |
- |
Total |
in mill. |
|
Revenues: |
13,117.20 USD |
7.76% |
Net Income: |
3,953.60 USD |
-8.87% |
Operating Cash Flow: |
4,594.00 USD |
- |
Cash and Cash Equivalents: |
2,730.00 USD |
- |
Valuation Ratios
|
Current |
Latest FY* |
P/E Ratio: |
31.76 |
23.71 |
P/S Ratio: |
9.68 |
7.23 |
P/BV ratio: |
4.89 |
3.65 |
P/CF Ratio: |
27.65 |
20.64 |
PEG: |
-3.72 |
-2.78 |
Earnings Yield: |
3.15% |
4.22% |
Dividend Yield: |
- |
- |
Market Capitalization |
|
Market Capitalization: |
129.7 bill. USD |
94.81 bill. USD |
Free Float Market Cap.: |
- USD |
- USD |
Market Cap. / Employee: |
- USD |
- USD |
Shares Outstanding: |
108.42 mill. |
|
Profitability
Gross Profit Margin: |
86.16% |
EBIT Margin: |
30.85% |
Net Profit Margin: |
30.14% |
Return on Equity: |
15.22% |
Return on Assets: |
11.95% |
Financial Strength
Liquidity I / Cash Ratio: |
79.75% |
Liquidity II / Quick Ratio: |
245.29% |
Liquidity III / Current Ratio: |
569.00% |
Debt / Equity Ratio: |
27.36% |
Dynam. Debt / Equity Ratio: |
154.70% |
Efficiency
Employees: |
- |
Personal Expenses / Employee: |
- USD |
Revenues / Employee: |
- USD |
Net Income / Employee: |
- USD |
Total Assets / Employee: |
- USD |
* Fiscal Year End: |
12/31/2023 |
Accounting Standard: |
US GAAP |